266 related articles for article (PubMed ID: 17593102)
1. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.
Morrissey C; Brown M; O'Sullivan J; Weathered N; Watson RW; Tenniswood M
Int J Urol; 2007 Jun; 14(6):545-51. PubMed ID: 17593102
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
Gupta S; Ahmad N; Nieminen AL; Mukhtar H
Toxicol Appl Pharmacol; 2000 Apr; 164(1):82-90. PubMed ID: 10739747
[TBL] [Abstract][Full Text] [Related]
4. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
6. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
[TBL] [Abstract][Full Text] [Related]
7. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
8. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
Floyd MS; Teahan SJ; Fitzpatrick JM; Watson RW
Prostate Cancer Prostatic Dis; 2009; 12(1):25-33. PubMed ID: 18475288
[TBL] [Abstract][Full Text] [Related]
9. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
11. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
[TBL] [Abstract][Full Text] [Related]
12. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M
Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
14. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
15. Study of the combined effect of X-irradiation and epigallocatechin-gallate (a tea component) on the growth inhibition and induction of apoptosis in human cancer cell lines.
Baatout S; Jacquet P; Derradji H; Ooms D; Michaux A; Mergeay M
Oncol Rep; 2004 Jul; 12(1):159-67. PubMed ID: 15201978
[TBL] [Abstract][Full Text] [Related]
16. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]